A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: Pharmacokinetic and pharmacodynamic rationale for dosing

Clinical Cancer Research

Volumn 13, Issue 3, 2007, Pages 986-993

  Fracasso, Paula M ^a   Burris III, Howard ^b   Arquette, Matthew A ^a   Govindan, Ramaswamy ^a   Gao, Feng ^a   Wright, Lisa P ^a   Goodner, Sherry A ^a   Greco, F Anthony ^b   Jones, Suzanne F ^b   Willcut, Noel ^b   Chodkiewicz, Catherine ^c   Pathak, Amit ^c   Springett, Gregory M ^c   Simon, George R ^c   Sullivan, Daniel M ^c   Marcelpoil, Raphaël ^d   Mayfield, Shelley D ^e   Mauro, David ^e   Garrett, Christopher R ^c  

^a USA   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d TriPath Imaging Inc   (United States)

^e BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER GROWTH; CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; FATIGUE; FEMALE; FEVER; HEAD AND NECK CARCINOMA; HUMAN; LARYNX CANCER; MALAISE; MALE; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; RECEPTOR BLOCKING; SINGLE DRUG DOSE; SKIN BIOPSY; SKIN MANIFESTATION; TOXICITY; TUMOR BIOPSY;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOPSY; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33847411438     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1542     Document Type: Article

References (23)

1. Mendelsohn J, Baird A, Fan Z, Markowitz SD. Growth factors and their receptors in epithelial malignancies. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, editors. The molecular basis of cancer. Philadelphia (PA): W.B. Saunders Company; 2001. p. 137-44.
2. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99.
3. Pfister D, Aliff TB, Kraus D, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiation therapy (RT) for locoregionally advanced, squamous cell head and neck cancer (SCCHN): preliminary evaluation of a new combined-modality paradigm. Proc Am Soc Clin Oncol 2003;22:495.
4. Gatzemeier U, Rosell R, Ramlau R, et al. Cetuximab (C225) in combination with cisplatin/vinorelbine vs. cisplatin/vinorelbine alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR) positive advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2003;22:642.
5. Kim ES, Mauer AM, Tran HT, et al. A phase II study of cetuximab, an IgG1 epidermal growth factor receptor blocking antibody, in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced non-small cell lung cancer: Final report. Proc Am Soc Clin Oncol 2003;22:642.
6. Kelly K, Hanna N, Rosenberg A, et al. A multicenter phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol 2003;22:644.
7. Trigo J, Hitt R, Koralewski P, et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study. J Clin Oncol (Meeting Abstracts) 2004;22:5502.
8. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
9. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004;22:2610-6.
10. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
11. Su YB, Kraus DH, Zelefsky MJ, et al. Concurrent cetuximab, cisplatin, and radiotherapy (RT) for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN): updated results of a novel combined modality paradigm. J Clin Oncol (Meeting Abstracts) 2005;23:5529.
12. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
13. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14.
14. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43.
15. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2005;23:8646-54.
16. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-87.
17. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001;7:1204-13.
18. World Health Organization. Handbook for reporting results of cancer treatment: Geneva (Switzerland): World Health Organization Offset Publications; 1979.
19. Khazaeli MB, LoBuglio A, Falcey J, Paulter V, Fetzer M, Waksal H. Low immunogenicity of a chimeric monoclonal antibody (MoAb), IM-C225, used to treat epidermal growth factor receptor-positive tumor [abstract 808]. Proc Am Soc Clin Oncol 2000;19:207a.
20. Saltz L, Rubin MS, Hochster HS, et al. Acne-like rash predicts response in patients treated with cetuximab (IM-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract]. Clin Can Res 2001;Suppl 7:3766s.
21. Saltz L, Kies M, Abbruzzese JL, Azarnia N, Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003;22:204.
22. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-77.
23. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;23:5235-46.